{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:30Z","timestamp":1793212110548,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013611","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000}}],"reference-count":41,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013611.pub2","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T06:33:55Z","timestamp":1689575635000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Vedolizumab for induction and maintenance of remission in Crohn's disease"],"prefix":"10.1002","volume":"2023","author":[{"given":"Samuel","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Monash Medical Centre; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Sinopoulou","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazaleh","family":"Aali","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"},{"name":"Institute for Health Informatics Research; University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Krishna","sequence":"additional","affiliation":[{"name":"Austin Health; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Sheng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; St Vincent's Hospital; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray K","family":"Boyapati","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; Monash Medical Centre; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"10.1002\/14651858.CD013611.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"s620","DOI":"10.14309\/00000434-201210001-01542","article-title":"Vedolizumab maintenance therapy for Crohn's disease: results of GEMINI II, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial","volume":"107","author":"Hanauer","year":"2012","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S624","DOI":"10.14309\/00000434-201210001-01550","article-title":"Vedolizumab induction therapy for Crohn's disease: results of GEMINI II, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial","volume":"107","author":"Sandborn","year":"2012","journal-title":"American Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD013611.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013611.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013611.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0007|cit7","first-page":"12","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the visible 2 randomised trial","volume":"1","author":"Vermeire","year":"2021","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Vermeire S D'Haens G Baert F Danese S Kobayashi T Loftus EV Efficacy and safety of vedolizumab subcutaneous formulation in patients with moderately to severely active Crohn's disease: results of the VISIBLE 2 study Journal of Gastroenterology and Hepatology 2020 35 Suppl 1 115","DOI":"10.1093\/ecco-jcc\/jjz203.022"},{"issue":"6 (Suppl 1)","key":"10.1002\/14651858.CD013611.pub2-BIB0009|cit9","first-page":"S","article-title":"The visible 2 phase 3 study of efficacy and safety of vedolizumab SC for moderate-to-severe Crohn's disease","volume":"158","author":"Vermeire","year":"2020","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013611.pub2-BIB0010|cit10","first-page":"S","article-title":"A phase 3 study of vedolizumab for induction and maintenance therapy in Japanese patients with moderate to severe Crohn's disease","volume":"156","author":"Ogata","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Ogata H Motoya S Watanabe K Kanai T Matsui T Suzuki Y A phase 3 study of vedolizumab for induction and maintenance therapy in Japanese patients with moderate to severe Crohn's disease Gastroenterology 2019 156 6 S 1109 10.1016\/S0016-5085(19)39732-X","DOI":"10.1016\/S0016-5085(19)39732-X"},{"issue":"3","key":"10.1002\/14651858.CD013611.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-019-01647-w","article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled phase 3 trial with exploratory analyses","volume":"55","author":"Watanabe","year":"2020","journal-title":"Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD013611.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-019-01647-w","article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled phase 3 trial with exploratory analyses","volume":"55","author":"Watanabe","year":"2020","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Pipek B Subcutaneous vedolizumab treatment for ulcerative colitis and Crohn\u2018s disease in clinical trial VISIBLE Gastroenterologie a Hepatologie 2020 74 6 558 61 10.48095\/ccgh2020558","DOI":"10.48095\/ccgh2020558"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Sandborn WJ Feagan B Reinisch W Smyth M Xu J Parikh A P497 Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6 Journal of Crohn's and Colitis 2014 8 Suppl 1 S274 5","DOI":"10.1016\/S1873-9946(14)60617-6"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0016|cit16","unstructured":"Vermeire S Colombel JF Feagan BG Sandborn WJ Sands BE Long-term efficacy of vedolizumab for Crohn's disease Journal of Crohn's and Colitis 2017 11 4 412 24"},{"issue":"8","key":"10.1002\/14651858.CD013611.pub2-BIB0017|cit17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007571.pub2","article-title":"Vedolizumab for induction and maintenance of remission in ulcerative colitis","author":"Bickston","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"20","key":"10.1002\/14651858.CD013611.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.12703\/P7-44","article-title":"Pathogenesis of Crohn's disease","volume":"7","author":"Boyapati","year":"2015","journal-title":"F1000Prime Reports"},{"issue":"12","key":"10.1002\/14651858.CD013611.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/ajg.2016.441","article-title":"Biomarkers in search of precision medicine in IBD","volume":"111","author":"Boyapati","year":"2016","journal-title":"American Journal of Gastroenterology"},{"issue":"5258","key":"10.1002\/14651858.CD013611.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1126\/science.272.5258.60","article-title":"Lymphocyte homing and homeostasis","volume":"272","author":"Butcher","year":"1996","journal-title":"Science"},{"issue":"9613","key":"10.1002\/14651858.CD013611.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD013611.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ibd.22977","article-title":"Mucosal healing in Crohn's disease: a systematic review","volume":"19","author":"De Cruz","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6-7","key":"10.1002\/14651858.CD013611.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","article-title":"Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)","volume":"52","author":"Eriksson","year":"2017","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"43","key":"10.1002\/14651858.CD013611.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.3748\/wjg.v27.i43.7572","article-title":"Minimum sample size estimates for trials in inflammatory bowel disease: a systematic review of a support resource","volume":"27","author":"Gordon","year":"2021","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0026|cit26","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2020"},{"issue":"5","key":"10.1002\/14651858.CD013611.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/gast.1996.v111.pm8898653","article-title":"Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7","volume":"111","author":"Hesterberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0028|cit28","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.2 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013611.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S001","DOI":"10.1093\/ecco-jcc\/jjab075.001","article-title":"OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn's disease: the SEAVUE study","volume":"15","author":"Irving","year":"2021","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD013611.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"Clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD013611.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD013611.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.5114\/aoms.2016.61915","article-title":"Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis","volume":"12","author":"Mo\u0107ko","year":"2016","journal-title":"Archives of Medical Science"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0034|cit34","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD013611.pub2-BIB0035|cit35","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"3","key":"10.1002\/14651858.CD013611.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease","volume":"43","author":"Shah","year":"2016","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD013611.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD013611.pub2-BIB0038|cit38","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn's disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"issue":"1","key":"10.1002\/14651858.CD013611.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJMe020157","article-title":"\u03b14 Integrins as therapeutic targets in autoimmune disease","volume":"348","author":"Andrian","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"28","key":"10.1002\/14651858.CD013611.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1097\/MD.0000000000000326","article-title":"PRISMA \u2013 efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"93","author":"Wang","year":"2014","journal-title":"Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013611.pub2-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013611","article-title":"Vedolizumab for induction and maintenance of remission in Crohn's disease","author":"Hui","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T01:20:03Z","timestamp":1760577603000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013611.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gut Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013611.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}